Jimeno A - Search Results

1

Vemurafenib: the road to personalized medicine in melanoma.

Amaria RN, Lewis KD, Jimeno A. Amaria RN, et al. Among authors: jimeno a. Drugs Today (Barc). 2012 Feb;48(2):109-18. doi: 10.1358/dot.2012.48.2.1745274. Drugs Today (Barc). 2012. PMID: 22384451 Review.

2

Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

Bowles DW, Kessler ER, Jimeno A. Bowles DW, et al. Among authors: jimeno a. Drugs Today (Barc). 2011 Nov;47(11):857-68. doi: 10.1358/dot.2011.47.11.1688487. Drugs Today (Barc). 2011. PMID: 22146228 Review.

3

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.

Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. Dasari A, et al. Among authors: jimeno a. Invest New Drugs. 2013 Feb;31(1):115-25. doi: 10.1007/s10637-012-9812-z. Epub 2012 Mar 14. Invest New Drugs. 2013. PMID: 22415798 Clinical Trial.

4

JAK2 inhibition for the treatment of hematologic and solid malignancies.

Harry BL, Eckhardt SG, Jimeno A. Harry BL, et al. Among authors: jimeno a. Expert Opin Investig Drugs. 2012 May;21(5):637-55. doi: 10.1517/13543784.2012.677432. Expert Opin Investig Drugs. 2012. PMID: 22493978 Review.

5

Crizotinib for the treatment of patients with advanced non-small cell lung cancer.

Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A. Bowles DW, et al. Among authors: jimeno a. Drugs Today (Barc). 2012 Apr;48(4):271-82. doi: 10.1358/dot.2012.48.4.1769835. Drugs Today (Barc). 2012. PMID: 22536569 Review.

6

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A. Amaria RN, et al. Among authors: jimeno a. Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Drugs Today (Barc). 2012. PMID: 22844657 Review.

7

Axitinib, a new therapeutic option in renal cell carcinoma.

Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Kessler ER, et al. Among authors: jimeno a. Drugs Today (Barc). 2012 Oct;48(10):633-44. doi: 10.1358/dot.2012.48.10.1860768. Drugs Today (Barc). 2012. PMID: 23110259 Review.

8

The development of regorafenib and its current and potential future role in cancer therapy.

Davis SL, Eckhardt SG, Messersmith WA, Jimeno A. Davis SL, et al. Among authors: jimeno a. Drugs Today (Barc). 2013 Feb;49(2):105-15. doi: 10.1358/dot.2013.49.2.1930525. Drugs Today (Barc). 2013. PMID: 23462625 Review.

9

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.

Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Jimeno A, et al. Clin Cancer Res. 2013 May 15;19(10):2766-74. doi: 10.1158/1078-0432.CCR-12-3654. Epub 2013 Apr 10. Clin Cancer Res. 2013. PMID: 23575478 Free PMC article. Clinical Trial.

10

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Narayanan V, et al. Among authors: jimeno a. Drugs Today (Barc). 2013 Apr;49(4):261-9. doi: 10.1358/dot.2013.49.4.1950147. Drugs Today (Barc). 2013. PMID: 23616953 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters